Associate Professor Jodie Ingles, Professor Joseph Powell and Professor Jerry Greenfield

Jodie-Ingles-Joseph-Powell-Jerry-Greenfield-Garvan-Institute

Garvan Institute researchers have been awarded three significant grants from the Medical Research Future Fund to advance cardiac research and improve patient outcomes.

Federal funding for major cardiovascular research projects at Garvan

From left to right: José Alquicira-Hernández, Seyhan Yazar and Joseph Powell

220408_Jose-Alquicira-Hernandez-Seyhan-Yazar-Joseph-Powell_Garvan-Institute

Most autoimmune diseases are easy to diagnose but hard to treat. A paper published today in Science proposes using your unique immune cell fingerprint to rapidly identify which treatments will work for your autoimmune disease.

An immune ‘fingerprint’ reveals path for better treatment of autoimmune diseases

Stuart_Tangye_Garvan_Institute

Professor Stuart Tangye’s work advancing rare immune disease research has received national recognition.

Garvan immunologist awarded 2024 Eureka Prize

Cristian David Pena Martinez, Associate Professor Sarah Kummerfeld and Professor Daniel Christ

Cristian-David-Pena-Martinez-Sarah-Kummerfeld-Danie-Christ-Martinez-Garvan-Institute.jpg

Innovative study of DNA’s hidden structures may open up new approaches for treatment and diagnosis of diseases, including cancer.

Researchers map 50,000 of DNA’s mysterious ‘knots’ in the human genome

Professor Peter Croucher accepting the Sally Crossing AM Award

Peter-Croucher_Sally-Crossing-award_Garvan-Institute.jpg

The Sally Crossing AM Award has been presented to Professor Peter Croucher for his pioneering research on the mechanisms that allow metastatic cancers to lie dormant in bone before reawakening.

Professor Peter Croucher recognised for research into dormant cancer cells

Professor Paul Timpson, Dr Brooke Pereira and Associate Professor Thomas Cox

brooke-thomas-paul_Garvan-Institute-v3.jpg

A molecule called nidogen-2 may be a key driver of pancreatic cancer progression and metastasis, offering a promising new treatment approach for this aggressive cancer, according to a Garvan Institute study.

Promising new target discovered in pancreatic cancer could boost chemotherapy and reduce spread

Bone deteriorated by multiple myeloma is regenerated after treatment with romosozumab (right) in a mouse model.

Multiple-myeloma-bone-disease-treatment_Garvan-Institute-4.jpg

Clinical trial explores a drug’s potential to rebuild myeloma bone damage, not just prevent it worsening.

Can an osteoporosis drug heal myeloma bone disease?

Dr Jennifer Snaith and Professor Jerry Greenfield

Jennifer_Snaith_and_Jerry_Greenfield_Garvan-Institute

The Garvan Institute has launched the RESET1 study to investigate semaglutide’s potential in reducing heart disease risk for people with type 1 diabetes.

New clinical trial targets heart health in type 1 diabetes

Dr Amanda Khoury and Professor Susan Clark

Amanda_Khoury_and_Susan_Clarke_Garvan-Institute

Using artificial intelligence, Garvan Institute researchers have found potential cancer drivers hidden in so-called ‘junk’ regions of DNA, opening up possibilities for a new approach to diagnosis and treatment.

New class of cancer mutations discovered in so-called ‘junk’ DNA

Ankur-Sharma_Garvan-Institute-4.jpg

Dr Ankur Sharma will join Garvan’s Translational Genomics Program to advance immunotherapies and the development of vaccines targeting cancer.

Leading cancer biologist joins Garvan

Paul-Timpson-and-David-Hermann_Garvan-Institute.jpg

A new trial will test whether ‘priming’ pancreatic cancer can make it more susceptible to chemotherapy.

Pancreatic cancer clinical trial to test new approach to treatment

Daniel-MacArthur-Garvan-Institute

A team led by Professor Daniel MacArthur has received MRFF funding to investigate safer use of advanced analytics, including AI, to improve the diagnosis of genetic diseases.

Significant MRFF funding to spearhead AI in rare disease diagnosis

CSL-Florey-Jose-Alquicira-Hernandez_Garvan-Institute.jpeg

An early career researcher at the Garvan Institute has been selected by the Australian Institute of Policy and Science as one of three finalists for a prestigious biennial award.

CSL Florey Next Generation Award shortlist recognises a rising star in the field of cellular genomics

221118_Amanda-Khoury_Garvan-Institute

Dr Amanda Khoury will take part in an acclaimed national program, becoming a role model for the next generation of scientists.

Garvan researcher announced as a Superstar of STEM

Amanda-Khoury2020_Garvan-Institute.jpg

A protein that maintains DNA’s 3D arrangement may be central to the health of human cells.

Study shines light on how DNA keeps its 3D shape

immunity-break-story_Garvan-Institute-2.jpg

Researchers have identified a new genomic signature that controls whether the immune system’s specialised ‘killer’ T cells activate or stand down, revealing 100 potential new drug targets for cancer and autoimmune disease.

Immune ‘brake’ reveals drug targets for cancer and autoimmune disease

Garvan_Institute_staircase.jpg

From immune dysfunction to cancer therapy resistance: eight projects funded to address critical health issues.

Garvan researchers secure NHMRC Investigator Grants

Associate Professors Liz Caldon and Clare Stirzaker

Liz_Caldon_and_Clare_Stirzaker_Garvan_Institute.jpg

The National Breast Cancer Foundation has backed two new projects at Garvan to support the development of improved treatment approaches for one of the hardest-to-treat breast cancers.

Triple-negative breast cancer research funded at Garvan

Joseph-Powell_Garvan-Institute.jpeg

The Garvan Institute and Illumina, a global genomics and human health company, are partnering on the $27 million TenK10K project to help transform the treatment of complex diseases, starting with autoimmune diseases. 

International partnership to map 50 million human cells and uncover genetic fingerprints of disease

Dr Ruth Pidsley, Dr Sharissa Latham and Professor Paul Timpson

CCNSW_grants_Garvan_Institute

Three new Garvan cancer projects will go ahead thanks to new funding.

Garvan cancer research projects given green light

Associate Professor Thomas Cox and Dr Elysse Filipe

Thomas-Cox-Elysse-Filipe-Garvan-Institute

Researchers have discovered how the mechanical properties of tumours can prime cancer cells to better survive their spread to other organs.

Softer tumours fuel more aggressive spread of triple-negative breast cancer

David-Thomas_Garvan-Institute.jpg

A DNA database of thousands of healthy older Australians is set to change how we determine which genes underpin disease.

Researchers uncover the genomics of health

deborah-burnett_Garvan-Institute.jpeg

Garvan-led researchers outline a strategy to generate future-proofed COVID-19 vaccines that can resist emergent new viral strains.

Researchers reveal a strategy for next-generation COVID-19 vaccines

John-Shine_Garvan-Institute.jpg

For his scientific leadership and pioneering research in molecular genetics Garvan’s Professor John Shine AC, has been elected as Fellow of the Royal Society.

Professor John Shine AC elected as Fellow of the Royal Society

Jose-Alquicira-and-Seyhan-Yazar-and-Joseph-Powell.jpeg

Researchers have a new lens by which to understand how genes impact disease.

New discovery to advance genomics-driven precision medicine

Susan-Clark_Garvan-Institute.jpg

By Professor Susan Clark FAA FAHMS from the Garvan Institute of Medical Research.

Insights from our genome and epigenome will help prevent, diagnose and treat cancer

Tri-Phan_Garvan-Institute.jpeg

The ACRF INCITe Centre will enable researchers to see immune cells and molecules move and interact below the surface of tumours and deep inside tissues.

Innovative research centre to image ‘dark space’ of cancer

kimberley-bracelet1680x1120.png

In August, we celebrate a significant milestone with Paspaley reaching $2 million in donations in support of Garvan’s cancer research. 

Paspaley’s jewellery with purpose

A phyllodes tumour's characteristic leaf-like cellular structure is not enough to identify it as malignant or benign, as in this borderline case.

Borderline_phyllodes_tumour_histology_Garvan_Institute

Researchers are a step closer to improved diagnosis for rare breast tumours called phyllodes tumours, thanks to new findings from the Garvan Institute of Medical Research. 

Biomarkers discovered for difficult-to-diagnose breast tumour

221114_Amelia-Parker-and-Thomas-Cox_Garvan-Institute

Molecular profiles of the matrix around non-small cell lung cancers identifies which tumours become aggressive and require more targeted treatment.

Tumour matrix profiling gives clues to progression of some lung cancers

Emeritus Professor Robert Blank, Professor Jacqueline Center and Dr Dana Bliuc 

Robert-Blank-Jacqueline-Center-Dana-Bluic-Garvan-Institute

Can you walk a kilometre? The answer can reveal clues about your future fracture risk. 

Walking fitness can predict fracture risk in older adults

Composite_photo_.png

Garvan researchers have revealed a reason why endocrine resistance develops in breast cancers and how to potentially treat it in patients.

Epigenetic therapy shows promise for endocrine-resistant breast cancer

Tri Phan, Jennifer Massey and Elissa Deenick, leaders of the OCCAMS multiple sclerosis research consortium.

Tri-Phan_Jennifer-Massey_Elissa-Deenick_OCCAMS

Researchers and clinicians across Australia unite to develop better ways to detect, prevent and treat multiple sclerosis.

Sydney researchers to lead multiple sclerosis study

Susan Clark, Tri Phan, Elissa Deenick and Marina Pajic

Elissa-Deenick-Marina-Pajic-Susan-Clark-Tri-Phan

A significant funding boost will help Garvan’s cancer and immunology researchers pursue new directions and form collaborations.

Personalised medicine research projects backed by major grants

Joanna Achinger-Kawecka and David Herrmann

Joanna-Achinger-Kawecka_David Herrmann

Garvan researchers investigating the ‘ecosystems’ of breast and pancreatic cancer have been awarded Ideas Grants from the National Health and Medical Research Council.

Innovative cancer research projects awarded NHMRC funding

Ira_Deveson_and_Andre_Reis_Garvan_Institute

New research provides the most comprehensive picture to date of the genomic diversity within and between First Nations communities across Australia.

Unique diversity of Indigenous Australians revealed by next-generation genomics

Scott_Perkins_Garvan_Chair_Board.jpg

We are pleased to announce the appointment of Mr Scott Perkins as Chair of Garvan's Board of Directors. 

New Chair for Garvan Institute of Medical Research

190618_Alex-Swarbrick_Garvan-Institute

Research into predictive biomarkers at Garvan has been recognised internationally with a significant funding boost.

International fellowship for Garvan breast cancer researcher

Paul Timpson and Marina Pajic at the Garvan Institute

Paul-Timpson-Marina-Pajic-Garvan-Institute

Garvan researchers will contribute to multi-institutional collaborations to overcome current challenges in cancer treatment.

Researchers unite for major national cancer projects

230828-Thomas-Cox_Jessica-Chitty_lowres_Garvan-Institute

Thomas Cox and Jessica Chitty at the Garvan Institute

230829-Thomas-Cox_Jessica-Chitty_Garvan-Institute

Early laboratory results in mice show the drug PXS-5505 increases survival when combined with chemotherapy in the treatment of pancreatic ductal adenocarcinomas.


Drug that targets scar-like tissue in tumours shows promise for aggressive pancreatic cancer

Clockwise from top left: Professor Joseph Powell, Professor Stuart Tangye, Dr Kishore Kumar and Dr Ira Deveson

Joseph-Powell-Stuart-Tangye-Kishore-Kumar-Ira-Deveson_Garvan-Institute

Four Garvan researchers will lead projects to harness genomics for improved diagnosis and treatment of disease.

Genomics Health Futures Mission funds medical research at Garvan

David Thomas at Project Prospect launch at Garvan

220317_David-Thomas-Project-Prospect_Garvan-Institute

The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives.

$185 million investment to fast-track treatments for rare and ‘untreatable’ cancers

ira-deveson-and-kishore-kumar_Garvan-Institute.jpeg

Garvan researchers have shown how new genomic sequencing technology can reduce the 'diagnostic odyssey' experienced by people with rare neurological and neuromuscular diseases.

Single test for over 50 genetic diseases will cut diagnosis from decades to days

Imaging showing cancer cells (green) being attacked by neutrophils (red) in the collagen structure (blue) of a tumour’s microenvironment. Credit: Jacqueline Bailey / Dr Chtanova's Innate and Tumour Immunology Lab at Garvan

230615_Cancer-cells-and-neutrophils-in-a-tumour-microenvironment-Credit-Jacqueline-Bailey_Garvan-Institute

Microbial therapy can activate neutrophils to destroy triple-negative breast cancer and other cancers.

Exposing cancers to bacteria reminds first responder immune cells which side they’re on

221118_Sean-Porazinski_Garvan-Institute

PanKind Foundation supports new study to develop tailored therapy for pancreatic cancer.

Accelerator Grant for pancreatic cancer researcher

Fluorescent imaging of retinal pigment epithelium. Credit: Dr Grace Lidgerwood

220726_Fluorescent-imaging-of-retinal-pigment-epithelium_Garvan-Institute

The discovery of molecular signatures of age-related macular degeneration will help with better diagnosis and treatment of this progressive eye disease.

Genetic clues to age-related macular degeneration revealed

Garvan_staircase-600x380.jpeg

The NHMRC has allocated $9 million to fund the critical research projects of five outstanding Garvan researchers.

Garvan researchers awarded five NHMRC Investigator Grants

Daniel-Christ-antibody-screen.jpeg

Key molecules involved in mammalian-meat anaphylaxis have had their structure revealed, paving the way for future treatments.

Genetic and molecular insights into dangerous tick bite-related meat allergy revealed

Joseph-Powell_new.png

Australian researchers uncover hidden genetic markers of glaucoma

Stem-cell models reveal glaucoma secrets

Deborah-Burnett.jpg

The 2023 NSW Premier’s Prize for Early Career Researcher of the Year (Biological Sciences) recognises Garvan’s Dr Deborah Burnett.

Dr Deborah Burnett honoured with NSW Premier’s Prize

Mandy-Ballinger-Garvan-Institute.jpg

In recognition of her work to improve lives for those with sarcoma, Dr Mandy Ballinger has received the Liddy Shriver Early Career Research Award.

Dr Mandy Ballinger honoured with international sarcoma award

Deborah_Burnett_Garvan_Institute

Prestigious fellowship recognises Dr Burnett’s exceptional research in immunology.

L’Oréal-UNESCO Fellowship awarded to Garvan’s Dr Deborah Burnett

Liz-Caldon-Garvan-Institute

By analysing more than 80 clinical trials, researchers at Garvan have identified genetic tests that predict which cancer patients are likely to benefit from PARP inhibitors in combination with chemotherapy.

Predicting cancer patient response to PARP inhibitors

bone-imaging-Garvan-Institute

Imaging technology developed at Garvan shows that bone-resorbing osteoclasts gather in distinct pockets, leading to new insights for osteoporosis and cancer treatment.

Cutting-edge imaging sheds new light on cells that break down bone

New research reveals how zero-calorie sweeteners rewire the brain into feeling hungry.

Why artificial sweeteners can increase appetite

Peter_Croucher_Garvan_Institute

Professor Peter Croucher has been honoured with an award from the American Society for Bone and Mineral Research.

Prestigious bone research award for Professor Peter Croucher

Professor Stuart Tangye

Prestigious award recognises Professor Stuart Tangye’s international leadership in immunology.

Professor Stuart Tangye elected as Fellow of the Australian Academy of Health and Medical Sciences

Edmund-Hofflin-Garvan-Institute-low-res.jpg

Rebekah and her son Edmund went through a diagnostic odyssey to find the cause of Edmund's symptoms

Edmund-autoimmune-diagnosisGarvan-Institute

A bout of strep throat was the start of a diagnostic odyssey. The discovery of a rare genetic variant led to an effective therapy.


Edmund’s rare genetic variant uncovered a life-changing treatment

230609_Benjamin-Kile_Garvan-Institute

Benjamin_Kile_Garvan-Institute.png

Professor Benjamin Kile, internationally recognised blood cell molecular biologist, will lead Garvan as its next Executive Director.

Explore our research

Our impact

Our people

News and resources

About us

Support Us

News

Featured Article

Garvan immunologist awarded 2024 Eureka Prize